Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70266 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von K Mancuso und 24 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Introduction
MGRS are new rare clinical entities, whose recognition and optimal management is evolving.
Methods
To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS receiving mainly novel treatments (between 2006 and 2021) in eight Italian centres. Based on renal biopsy, patients were divided into two subgroups: AL amyloidosis (70%, n = 42) and other‐MGRS (30%, n = 18).
Results
Baseline characteristics follow typical manifestations of MGRS disorders in terms of small clonal burden, laboratory and clinical features. More patients with AL amyloidosis had monotypic lambda light‐chain disease, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min and nephrotic proteinuria than other‐MGRS group. The most widely used drug was bortezomib, and about one‐third of patients underwent ASCT. Overall response rate was 86% with no differences in the two subgroups. However, high‐quality hematologic responses ≥very good partial response (VGPR) were greater in AL amyloidosis than in other‐MGRS group (67% vs 28%, p = 0.015). The depth of haematological response influenced renal response, obtained in 32 (59%) of evaluable patients, similarly in the subgroups. Indeed, 75% patients with ≥ VGPR ( p = 0.049) and none with stable disease ( p ≤ 0.001) obtained a renal response. No association between renal response and histotypes ( p = 0.9) or type of first‐line therapy ( p = 0.3) was found. At a median follow‐up of 54.4 months (IQR 24.8–102.8), median progression‐free survival (PFS) was 100.1 months (95% CI 34.9–NR), and median overall survival not reached (95% CI 129.8–NR). No significant difference emerged between the two groups in terms of survival outcomes. Achieving ≥ VGPR was confirmed as the main independent predictor of prolonged PFS in the general population (HR = 0.29, p = 0.023) and AL amyloidosis group (HR 0.23; p = 0.023). Preserved renal function at diagnosis was predictive of improved PFS in the AL amyloidosis group (eGFR ≥ 60 mL/min: HR = 0.003; p = 0.018; eGFR 30–60 mL/min: HR = 0.04, p = 0.046).
Conclusion
Further research is warranted to develop standardised response criteria and treatment strategies to improve MGRS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
- Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy.
- Hematology Department, Careggi Hospital, Florence, Italy.
- Hematology-Azienda Policlinico Umberto I-Department of Translational and Precision Medicine-Sapienza, University of Rome, Roma, Italy.
- Department of Medical Science, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
ORCID-Profile: K Mancuso, E Antonioli, A Gozzetti, S Barbato, P Tacchetti, I Rizzello, V Solli
Förderung
- Ministero della Salute
Zitieren
APA
Mancuso, K., Mina, R., Rocchi, S., Antonioli, E., Petrucci, M. T., Fazio, F., Gozzetti, A., Salvini, M., Cartia, C. S., Bertuglia, G., Patriarca, F., Dalla Palma, A. B., Barbato, S., De Cicco, G., Bigi, F., Favero, E., Tacchetti, P., Pantani, L., Rizzello, I., …, & Zamagni, E. (2024). Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.70266
Vancouver
Mancuso K, Mina R, Rocchi S, Antonioli E, Petrucci MT, Fazio F, et al. Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study. Cancer Medicine. 2024. doi:10.1002/cam4.70266
BibTeX
@article{Mancuso2024,
author = {Mancuso, K and Mina, R and Rocchi, S and Antonioli, E and Petrucci, M T and Fazio, F and Gozzetti, A and Salvini, M and Cartia, C S and Bertuglia, G and Patriarca, F and Dalla Palma, A B and Barbato, S and De Cicco, G and Bigi, F and Favero, E and Tacchetti, P and Pantani, L and Rizzello, I and Puppi, M and Talarico, M and Solli, V and Kanapari, A and Cavo, M and Zamagni, E},
title = {Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70266}
}
EUVIMED